DNA Next Generation Sequence in the Prevention of Infectious Complications After Transrectal Prostate Biopsy - Vladimir Mouraviev

(Length of discussion ~ 6 minutes)

E. David Crawford hosts a discussion with Vladimir Mouraviev on a trial regarding infection and sepsis following transrectal ultrasound-guided prostate biopsies and the use of next-generation sequencing to identify multiple organisms that pose an infection risk following these biopsies. A key finding of the trial was that based on these results, the targeted prophylaxis was individualized in three cases with no urosepsis and other infectious complications occurred within 30 days after biopsy in all patients.

Additional Content on Transrectal Ultrasound-Guided Prostate Biopsy

CUA 2017: Correlation of Transperineal Prostate Biopsy-Detected Cancer with Magnetic Resonance Imaging-Predicted Lesion in Patients with Previous Negative Transrectal Ultrasound-Guided Prostate Biopsies

"Targeted" prophylaxis: Impact of rectal swab culture-directed prophylaxis on infectious complications after transrectal ultrasound-guided prostate biopsy.

AUA 2017: Risk factor assessment for fluoroquinolone resistant E. coli (FRE) in bowel flora is not sufficiently discriminatory: the case for a pre-biopsy rectal swab in all patients.

Effect of patient position on pain scales during transrectal ultrasound-guided prostate biopsy.

Biographies

E. David Crawford

Vladimir Mouraviev, M.D., Ph.D., received his medical school training and surgical internship at State Military Medical Academy in Saint Petersburg, Russia, and went on military service as a surgeon.  Vlad completed his surgical and urological residency at the Department of Surgery of the same Academy specializing in urogenital injuries, reconstructive and general urology, eventually becoming an assistant professor in surgery and urology. He is currently a Urologist at the Florida Cancer Institute, Davenport, FL